

# Zelira Therapeutics Ltd

08:49 22 Aug 2018

## Zelda Therapeutics strengthens Scientific and Medical Advisory Board with two appointments

Zelda Therapeutics Ltd (ASX:ZLD) (OTCBB:ZLDAF) has added clinical expertise and depth to its Scientific and Medical Advisory Board through the appointment of two medicinal cannabis experts.

Professor David Casarett and Dr Dustin Sulak are internationally recognised as key opinion leaders in the clinical use of medicinal cannabis and are both based in the United States.

### READ: Zelda Therapeutics attracts new managing director, Dr Richard Hopkins

The appointments support the development of Zelda's novel medicinal cannabis therapies for autism, insomnia and cancer.

Zelda's managing director Dr Richard Hopkins said, "We are delighted Dr Casarett and Dr Sulak have agreed to join our Scientific and Medical Advisory Board.

"They bring extensive expertise in the use of medicinal cannabis that will inform our clinical programs for indications including autism, insomnia and cancer.

"Their ability to access US-based patient groups will also support our strategy to bring Zelda-branded products to market."

Professor Casarett is a leading palliative care physician and researcher at Duke University in North Carolina with a core interest in medicinal cannabis.

Dr Sulak is a high-profile medicinal cannabis practitioner who has treated more than 18,000 patients in the US.

### World-class advisory board

Other members of the board are Professor Manuel Guzmán, Dr Cristina Sánchez and Dr Noah Federman.

Professor Guzmán is Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and Dr Sánchez is an Assistant Professor at Complutense University, Madrid, Spain.

Dr Federman is director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles), part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre.

### READ: Zelda Therapeutics progresses medicinal cannabis brain cancer research

Zelda is an Australian-based bio-pharmaceutical company focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company has a two-pronged strategy comprising:

**Price:** 0.058

**Market Cap:** \$50.72 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** ZLD

**Listing:** ASX

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.091	0.04

**Sector:** Cannabis

**Website:** [www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)

#### Company Synopsis:

*Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.*

action@proactiveinvestors.com.au

- A human clinical trial program focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).